A group of researchers has found a new way to limit excessive immune responses, which may point in a new direction for research in and treatment of e.g. autoimmune diseases.
Researchers from Aarhus University Hospital and Aarhus University in Denmark in collaboration with researchers from Colorado in the United States have found a new way to treat the inflammation involved in chronic diseases such as psoriasis, asthma and HIV. A group of transmitter substances (cytokines) in the immune system, the so-called IL-1 family, has been shown to play an important role in many of these diseases by regulating the body’s immune responses.
Professor Charles A. Dinarello from University of Colorado Denver is also an honorary doctor at Aarhus University. He is an expert in regulation and transmission of these cytokines. He is primarily known for discovering the important cytokine IL-1(-?), which plays an important role in countless diseases. In collaboration with Charles Dinarello, the Danish researchers have investigated a more efficient way of reducing the effect of the IL-1 family and in this way improve treatment of chronic inflammatory diseases.
Previous research has often focused on blocking a single cytokine or signaling pathway at a time. However, many diseases and sequela are driven by more than one cytokine. This has caused researchers to wonder if it could be possible to block more important signaling pathways of the IL-1 family at the same time, and in this way make it possible to develop better treatments. The researchers try to find a broader anti-inflammatory treatment impacting several important cytokines at the same time, but also trying to avoid that this causes unintended side-effects.
In this study, the researchers have investigated if a receptor (IL-1R3), which is not just involved in the signaling of one but six different inflammatory cytokines in the IL-1 family, could be a possible target in the treatment of chronic inflammatory disease. Using an antibody to block the effect of IL-1R3, it was possible for the researchers to investigate the effects in both studies on cells and mice.
In this way, researchers could study some of the consequences of the blocking of this receptor on the immune system. At the same time, the researchers specifically studied the effect of blocking IL-1R3 in mice with either gout, acute allergic inflammation (asthma) or psoriasis.
– The experiments showed that it was possible to effectively block the receptor and reduce manifestation of diseases, which underlines the potentials in our new approach, says MD and PhD Jesper Falkesgaard Højen.
– Even though new questions arise as a consequences of these results, we have managed to describe a new and effective approach to block IL-1 family driven inflammation, and in this way we have possibly contributed with a new direction to study and treat chronic inflammatory conditions driven by the IL-1 family.
Learn more: Danish-American research presents new ways of developing treatment of chronic inflammation
The Latest on: Autoimmune diseases
[google_news title=”” keyword=”autoimmune diseases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Autoimmune diseases
- COVID patient's strange symptoms save her from deadly undiagnosed diseases. Here's what doctors discovered.on April 26, 2024 at 5:33 pm
Vicky Dennis went to the hospital with strange symptoms when she had COVID. Doctors found she had two undiagnosed, life-threatening diseases and needed a liver transplant to survive.
- Anti-Inflammatory Use May Reduce PD Risk in Patients With Autoimmune Diseaseson April 26, 2024 at 6:33 am
Researchers examined the relationship between exposure to anti-inflammatory therapy and the incidence of Parkinson disease in patients with autoimmune conditions.
- What It’s Like to Live With Neurologic Lyme Disease: A Patient Perspectiveon April 26, 2024 at 6:24 am
Diagnosing patients with neurologic Lyme disease can take upwards of 2 years, which Maria Arini Lopez discovered first-hand in the spring of 2021.
- Yoga practices to follow to manage autoimmune disorderson April 25, 2024 at 8:30 pm
Yoga helps manage autoimmune conditions by promoting relaxation, reducing inflammation, and supporting well-being. Techniques include gentle poses, de ...
- Fever, swollen glands, fatigue, rash and joint pain? Know how to identify autoimmune diseaseson April 25, 2024 at 6:45 pm
What complicates matters is that symptoms may overlap with other diseases and triggers may be unknown, says internal medicine expert Dr Suranjit Chatterjee ...
- Patients of autoimmune liver disease treated with immune suppressants have lower prevalence of apical periodontitis: Studyon April 24, 2024 at 6:30 am
Patients of autoimmune liver disease treated with immune suppressants have a lower prevalence of apical periodontitis suggests a study published in the Journal of Endodontics.Autoimmune ...
- How myeloid cell replacement could help treat autoimmune encephalomyelitison April 19, 2024 at 5:40 am
Autoimmune conditions such as multiple sclerosis (MS) are disorders of the immune system associated in this case with demyelination of the central nervous system (CNS). The term demyelination ...
- Taking stock of the frenzied push into autoimmune diseaseon April 18, 2024 at 6:13 am
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Good morning! This is a ...
- Cullinan Targets Autoimmune Market, Nabs $280M in Private Placementon April 17, 2024 at 5:00 am
Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus ...
- Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equityon April 16, 2024 at 12:32 pm
Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.
via Bing News